Medicare Enrolled
Dr. Mohammed Ogaily, M.D.
Medical Oncology · Brownstown Twp, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ogaily from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ogaily?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ogaily
Dr. Mohammed Ogaily is a medical oncology specialist in Brownstown Twp, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Ogaily performed 77,861 Medicare services across 1,860 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ogaily received a total of $7,994 from 71 pharmaceutical and/or device companies across 372 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ogaily is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 11% volume in MI
$7,994 industry payments
Medicare Practice Summary
Medicare Utilization ↗77,861
Medicare services
Top 11% in MI for medical oncology
1,860
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,893 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
40,800 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
17,850 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 8,940 | $18 | $37 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,814 | $0 | $3 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,700 | $1 | $4 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,282 | $8 | $23 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
619 | $11 | $42 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
534 | $12 | $51 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
505 | $91 | $376 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
427 | $103 | $443 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
345 | $138 | $528 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
267 | $50 | $221 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
255 | $16 | $66 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
236 | $1 | $5 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
145 | $23 | $96 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
136 | $23 | $94 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
129 | $134 | $576 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
116 | $1 | $9 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
113 | $51 | $214 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
108 | $63 | $206 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
93 | $61 | $265 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
91 | $19 | $87 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
66 | $44 | $185 |
| New patient office visit, complex (60-74 min) | 60 | $170 | $648 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
47 | $92 | $294 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
32 | $18 | $67 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
31 | $17 | $81 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
31 | $122 | $491 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
25 | $41 | $113 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
24 | $63 | $328 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
20 | $95 | $392 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
20 | $4 | $18 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
54.0% high complexity
42.4% medium
3.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,994
Total received (2018-2024)
Avg $1,142/year across 7 years
Top 29% in MI for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
71
Companies
372
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,964 (87.1%)
Other
Charitable contributions, space rental, and other categories
$684 (8.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$345 (4.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,331
2023
$1,960
2022
$1,856
2021
$1,180
2020
$209
2019
$327
2018
$132
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$255
PFIZER INC.
$164
Novartis Pharmaceuticals Corporation
$158
ABBVIE INC.
$146
Daiichi Sankyo Inc.
$110
GENZYME CORPORATION
$99
Takeda Pharmaceuticals U.S.A., Inc.
$85
Incyte Corporation
$83
Merck Sharp & Dohme LLC
$75
Eisai Inc.
$74
SOBI, INC
$69
E.R. Squibb & Sons, L.L.C.
$59
Janssen Pharmaceuticals, Inc
$58
Astellas Pharma US Inc
$57
Janssen Biotech, Inc.
$57
RECORDATI_RARE_DISEASES_INC.
$54
BeiGene USA, Inc.
$53
Celgene Corporation
$53
ARRAY BIOPHARMA INC
$53
PharmaEssentia USA Corporation
$48
Blueprint Medicines Corporation
$45
Acrotech Biopharma Inc.
$45
AstraZeneca Pharmaceuticals LP
$41
Gilead Sciences, Inc.
$39
GlaxoSmithKline, LLC.
$34
Aveo Pharmaceuticals, Inc.
$33
EMD Serono, Inc.
$28
Alexion Pharmaceuticals, Inc.
$28
Genmab U.S., Inc.
$27
Regeneron Healthcare Solutions, Inc.
$27
Octapharma USA, Inc.
$25
TAIHO ONCOLOGY, INC.
$23
Rigel Pharmaceuticals, Inc.
$23
Lilly USA, LLC
$19
Apellis Pharmaceuticals, Inc.
$19
Stemline Therapeutics Inc.
$17
Pharmacosmos Therapeutics Inc.
$17
Exelixis Inc.
$16
SERVIER PHARMACEUTICALS LLC
$14
Top 3 companies account for 24.8% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$781
Genentech USA, Inc.
$516
Amgen Inc.
$489
PFIZER INC.
$427
Takeda Pharmaceuticals U.S.A., Inc.
$307
NOVARTIS PHARMACEUTICALS CORPORATION
$299
GENZYME CORPORATION
$264
E.R. Squibb & Sons, L.L.C.
$261
ABBVIE INC.
$217
AstraZeneca Pharmaceuticals LP
$210
Daiichi Sankyo Inc.
$208
Janssen Pharmaceuticals, Inc
$202
Astellas Pharma US Inc
$180
Merck Sharp & Dohme LLC
$178
Regeneron Healthcare Solutions, Inc.
$177
SANOFI-AVENTIS U.S. LLC
$176
Celgene Corporation
$155
Seagen Inc.
$146
BeiGene USA, Inc.
$144
Incyte Corporation
$144
Pharmacosmos Therapeutics Inc.
$141
Eisai Inc.
$135
Lilly USA, LLC
$132
PharmaEssentia USA Corporation
$115
ARRAY BIOPHARMA INC
$112
Gilead Sciences, Inc.
$106
Janssen Biotech, Inc.
$100
GlaxoSmithKline, LLC.
$98
AVEO Pharmaceuticals, Inc.
$96
SOBI, INC
$85
EMD Serono, Inc.
$76
Alexion Pharmaceuticals, Inc.
$70
Rigel Pharmaceuticals, Inc.
$65
Exelixis Inc.
$64
Pharmacyclics LLC, An AbbVie Company
$64
RECORDATI_RARE_DISEASES_INC.
$54
Genmab U.S., Inc.
$53
Dova Pharmaceuticals
$53
Blueprint Medicines Corporation
$45
Acrotech Biopharma Inc.
$45
Aveo Pharmaceuticals, Inc.
$44
Adaptive Biotechnologies Corporation
$43
Myriad Genetic Laboratories, Inc.
$43
EISAI INC.
$41
Bayer Healthcare Pharmaceuticals Inc.
$40
Apellis Pharmaceuticals, Inc.
$37
MorphoSys, US Inc.
$37
ADC Therapeutics America, Inc.
$36
Ipsen Biopharmaceuticals, Inc
$34
Stemline Therapeutics Inc.
$32
Blue Earth Diagnostics Limited
$32
SERVIER PHARMACEUTICALS LLC
$31
Kite Pharma, Inc.
$25
Octapharma USA, Inc.
$25
Pharmacyclics LLC, an AbbVie Company
$24
AMAG Pharmaceuticals, Inc.
$24
TAIHO ONCOLOGY, INC.
$23
Sirtex Medical Inc
$21
CTI BioPharma Corp.
$20
Sobi, Inc
$19
TerSera Therapeutics LLC
$19
Mylan Institutional Inc.
$18
Karyopharm Therapeutics Inc.
$18
Puma Biotechnology, Inc.
$16
Taiho Oncology, Inc.
$16
Deciphera Pharmaceuticals Inc.
$16
MACROGENICS, INC.
$15
Bayer HealthCare Pharmaceuticals Inc.
$15
Fortovia Therapeutics, Inc.
$14
PUMA BIOTECHNOLOGY, INC.
$12
Merck Sharp & Dohme Corporation
$12
Top 3 companies account for 22.3% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AYVAKIT · Alecensa · Axumin · BAVENCIO · BELEODAQ · BESREMI · BEVESPI AEROSPHERE · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CREON · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ENHERTU · ENJAYMO · EPKINLY · EVENITY · Empaveli · Enhertu · Epkinly · Erleada · FERAHEME · FOTIVDA · FRUZAQLA · Fabhalta · GAZYVA · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MARGENZA · MEKINIST · MONJUVI · MONOFERRIC · Monoferric · NERLYNX · NINLARO · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OPDIVO · OPDUALAG · Ogivri · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SYLVANT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TEPMETKO · TUKYSA · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VELCADE · VENCLEXTA · VERZENIO · Vanflyta · Venclexta · Vonjo · XARELTO · XPOVIO · XTANDI · Xtandi · ZEJULA · Zoladex · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
16
Per 100K population
0.9
County median income
$59,521
Nearest hospital
COREWELL HEALTH TRENTON HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ogaily is a mixed practice specialist, with above-average Medicare volume (top 11% in MI), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ogaily experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Ogaily performed 40,800 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ogaily receive payments from pharmaceutical companies?
Yes. Dr. Ogaily received a total of $7,994 from 71 companies across 372 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ogaily's costs compare to other medical oncologists in Brownstown Twp?
Dr. Ogaily's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ogaily) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Brownstown Twp
Browse medical oncologists in Brownstown Twp ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in MI
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in MI
Which MI medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology